SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
Subscribe To Our Newsletter & Stay Updated